Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease, more common in women of childbearing age. Ocular manifestations of SLE are common and may lead to permanent blindness from the underlying disease or therapeutic side effects. Keratoconjunctivitis sicca is the most common manifestation.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by production of numerous antibodies that may affect multiple organ systems. 9 out of 10 adults with lupus are women and most women who develop lupus are between the ages of 15 and 44 [1] . Lupus is thought to develop due to an interaction between genetic susceptibility and environmental triggers. Previous studies have identified a number of genes referred to as "lupus susceptibility genes," the presence of which are thought to increase the likelihood of developing lupus. This increased susceptibility may be made possible, at least in part, due to differences related to hormones and sex chromosomes. However, to what extent these sex differences contribute to the development of lupus is largely unknown. About one-third of patients suffering from SLE have ocular manifestations and also a marker for overall systemic disease activity [2] . SLE can affect the eye in a variety of ways. Findings may include abnormalities of the eyelid, ocular adnexa, keratoconjunctivitissicca, iridocyclitis, retinal vasculitis, vaso-occlusive disorder, choroidopathy and optic neuropathy.
Keratoconjunctivitissicca (KCS) is the most common manifestation while retinal and choroidal involvements are most associated with visual loss [3] . The prevalence of KCS among patients with SLE is approximately 25% [4] .
The incidence of retinal involvement in SLE is 7-26 %. It is one of the most common vision-threatening complications of SLE with an incidence of up to 29 % in patients with active systemic disease [5] . Orbital involvement is a rare manifestation of SLE. Typical lesions of discoid lupus erythematosus are slightly raised, scaly, and atrophic rarely affecting the eyelids. The incidence of SLE in patients with scleritis is about 1% (Sainz de la et al 1994). Episcleritis is generally a benign inflammation of the episclera and typically occurring in young females with incidence 2.4% in SLE [6] . Corneal epitheliopathy, scarring, ulceration and filamentary keratitis can be found secondary to keratoconjunctivitissicca. More rare corneal complications include peripheral ulcerative keratitis [7] , which can be a marker of active systemic disease activity. The prevalence of SLE in patients with uveitis varies from 0.1% to 4.8%. Optic nerve involvement in patients with SLE may be in the form of optic neuritis, ischemic optic neuropathy and papilledema, and it occurs in around 1 % of SLE patients [8] . Lupus choroidopathy serves as a sensitive indicator of lupus activity. SLE retinopathy is believed to be an immune complex-mediated vasculopathy. In Bangladesh there is no broad-based study about ocular manifestations of SLE.
In this study, a cross sectional study was done for the evaluation of ocular manifestations of SLE in Bangladeshi female patients. with ophthalmic manifestations. Criteria for a mild/moderate and severe flares were developed for use in SELENA trial [10] .
Materials and Methods
Informed consent: For this study, a well informed, voluntarily signed written consent had been taken in an understandable local language from the study subjects.
Confidentiality: All the research data were coded with special ID and stored in a locked cabinet. Only research personnel were allowed to access the data. reported that ocular manifestations are common in SLE however they did not state the rate of presence of ocular manifestations.
Also, in agreement with the findings of the current study, previous study found that the majority of SLE patients do not develop ocular symptoms throughout the course of their illness [7] . In the present study, each of the discoid lesion and the periorbital edema that discoid lesion had affected only 6% of patients with SLE [11] .
In the present study 24 (28.5%) patients had manifestation of dry eye. Dry eye syndrome was frequently reported in patients with SLE. Several studies found that dry eye is the commonest eye manifestation in SLE being affecting 36.7% [12] , 39.5% [6] and 50% [13] of the patients. Klejnbergand Moraes found that the dry eye syndrome was diagnosed in 31.4% of the lupus patients [14] .
Probably, dry eye is the most common complication in SLE.
Because this disease interfere the natural tear production and chemical levels of the body, leading to drying out various parts of the body. In the present study, 3 patients (3.5%) had cataract. 
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The results of the current study also revealed that the SLEDAI score is significantly higher in SLE patients with ocular manifestations than those without ocular manifestations. In agreement with our results, Silpa-Archa et al. 2015, reported that ocular manifestations are common in SLE and presence of ocular symptoms is correlated to systemic disease activity.
Conclusion
Ocular affection is frequent in female SLE patients. Dry eyes and retinopathy (especially cotton-wool spots) are the most common findings. Anti-phospholipids, lupus renal manifestations and active disease are significantly related to eye affection especially retinopathy among female SLE patients. In the most active time of a female is her child-bearing age, which is most commonly affected by SLE and its debilitating ocular manifestations. Early diagnosis and prompt treatment can give these women a light of hope.
Recommendation
From the finding of this study we recommend to carry out longer and larger multi-centric prospective studies.
Further studies are necessary to see the long term ophthalmic manifestations in patients with SLE and follow up of those patients which may be beneficial to improve their ophthalmic & overall conditions and for a better management. Early recognition by the rheumatologist, prompt assessment by the ophthalmologist and coordinated treatment strategies are key to reducing the ocular morbidity associated with this disease.
